Epigenetics Drugs and Diagnostic Technologies Market, by Type (Epigenetic Drugs, (DNMT Inhibitors (Azacitidine and Decitabine), HDAC Inhibitors (Vorinostat, and Romidepsin) and Others) and Epigenetics Diagnostic Technologies (DNAMethylation and CHIP Technology) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
Gene mutations often result in the disruption of normal processing of genes and leads to the development of diseases. However, recently discovered epigenetic alterations have shown the potential to greatly influence tumoral response to therapy regimens. Such epigenetic alterations have proven to be dynamic, and thus could be restored. Due to their reversible nature, the promising opportunity to improve chemotherapy response using epigenetic therapy has arisen. Potential epidrug candidates can be found through a process known as drug repositioning or repurposing, a promising strategy for the discovery of novel potential targets in already approved drugs. At present, novel epidrug candidates have been identified in preclinical studies and some others are currently being tested in clinical trials, ready to be repositioned. The main focus of epidrug repurposing is the development of agents with one indication only, while giving patients lower cost therapies and a novel precision medical approach to optimize treatment efficacy and reduce toxicity. Epigenetic drugs are commonly used in the treatment of infections, cancer, diabetic retinopathy, cardiac dysfunction, schizophrenia, and mental problems including posttraumatic stress disorder. They are categorized into four classes: hydroxamates (vorinostat, belinostat, panobinostat), benzamides (entinostat, chidamide), cyclic peptides (romidepsin), and aliphatic acids.
Market Dynamics
Increasing new product launches, and mergers and acquisitions by key market players is expected to drive the global epigenetics drugs & diagnostic technologies market growth. For instance, on November 4, 2021, Epizyme, Inc., a U.S. based clinical-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EZM0414, the company’s novel, first-in-class, oral SETD2 inhibitor, as an investigational agent for the treatment of adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL). The company has also initiated a Phase 1/1b study to evaluate safety and determine the optimal dose of EZM0414.
Key features of the study:
This report provides an in-depth analysis of the global epigenetics drugs & diagnostic technologies market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global epigenetics drugs & diagnostic technologies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global epigenetics drugs & diagnostic technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epigenetics drugs & diagnostic technologies market
Detailed Segmentation:
Global Epigenetics Drugs and Diagnostic Technologies Market, By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Others
Epigenetics Diagnostic Technologies
DNAMethylation
CHIP Technology
Global Epigenetics Drugs and Diagnostic Technologies Market, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
Regenacy Pharmaceuticals, Inc.
Astex Pharmaceuticals
4SC AG
CellCentric Ltd.
Celleron Therapeutics Ltd.
Bristol-Myers Squibb Company
Oryzon Genomics S.A.
ChromaMedicine, Inc.
Epizyme, Inc.
EpiGentek Group Inc.
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Type
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis